AEHR
Aehr Test Systems
AEHR trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over AEHR overall, supported by stronger valuation and lower modeled downside.
AEHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Under pressure | |
| Strong |
AEHR's revenue and balance sheet are currently strong, and its profitability is stable, but its cash flow is under pressure.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
AEHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $0.69 | -99% |
| Fair | 44x | $2.18 | -96% |
| Expensive | 83x | $4.16 | -93% |
| Current | 1,221x | $61.04 | — |
Historical ranges are pointers, not guarantees.
AEHR's PE is in its expensive range at 1221x.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over AEHR in the historical PE scenario, which offers more potential upside but is not a forecast.
AEHR Forward outlook
There aren't enough analyst estimates for AEHR to show an outlook.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
AEHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.05 | +$0.27 |
| Q2 2026 | -$0.23 | -$0.10 |
| Q1 2026 | -$0.38 | -149% |
| Q4 2025 | -$0.30 | -140% |
| Q3 2025 | -$0.22 | -122% |
| Q2 2025 | -$0.13 | -112% |
| Q1 2025 | $0.78 | +50% |
| Q4 2024 | $0.75 | +5.6% |
AEHR has returned to profit: it earned $0.05 per share over the past year, after losing money the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over AEHR on earnings, with more consistent year-over-year improvement.
AEHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33M | +201% |
| Q2 2026 | $18.8M | +34% |
| Q1 2026 | $10.3M | -44% |
| Q4 2025 | $9.9M | -27% |
| Q3 2025 | $11M | -16% |
| Q2 2025 | $14.1M | -15% |
| Q1 2025 | $18.3M | +142% |
| Q4 2024 | $13.5M | -37% |
AEHR's revenue is growing: $33M last quarter, up 201% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +55 points |
| Q2 2026 | -6.4% | +16 points |
| Q1 2026 | -41% | -35 points |
| Q4 2025 | -47% | -36 points |
| Q3 2025 | -37% | -38 points |
| Q2 2025 | -23% | -38 points |
| Q1 2025 | -6.1% | +21 points |
| Q4 2024 | -11% | -37 points |
AEHR's operating margin was 18% last quarter, up 55 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over AEHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over AEHR on profitability, with a higher operating margin.
AEHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.1M | -$1.4M |
| Q2 2026 | $1.7M | +$6.8M |
| Q1 2026 | -$3.8M | -$502K |
| Q4 2025 | -$1.6M | +$4.6M |
| Q3 2025 | -$1.7M | -177% |
| Q2 2025 | -$5.1M | -535% |
| Q1 2025 | -$3.3M | -$174K |
| Q4 2024 | -$6.2M | -$5.5M |
AEHR has burned cash in most quarters: −$7M over the past year, against −$16M the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over AEHR on cash generation, producing positive trailing cash flow while its opponent burns cash.
AEHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.3% | +2.9M shares |
| 1 year | +12% | +3.6M shares |
| 3 years | +15% | +4.3M shares |
AEHR has 34M diluted shares, up 12% from a year ago.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over AEHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
AEHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -16.1x | Net Cash |
| Q4 2024 | -68.8x | Net Cash |
| Q3 2024 | -5.4x | Net Cash |
| Q2 2024 | -4.6x | Net Cash |
| Q1 2024 | -3.5x | Net Cash |
| Q4 2023 | -2.6x | Net Cash |
| Q3 2023 | -2.9x | Net Cash |
| Q2 2023 | -2.2x | Net Cash |
AEHR has more cash than debt.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
AEHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 7.9 | Oversold |
AEHR's weekly RSI is 44 (neutral) and its Stochastic is 8 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
AEHR PE vs Technology Sector
| Metric | AEHR | Sector median | Relative |
|---|---|---|---|
| PE | 1,221x | 28x | 4,282% above |
| PE % | 100 | 35 | 65 pts above |
AEHR is trading at 1221x earnings, a 4282% premium to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over AEHR on valuation relative to its sector.
AEHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.7 | 16% below |
| 20 week MA | $82.8 | 26% below |
| 50 week MA | $66.6 | 8.3% below |
| 100 week MA | $41.3 | 48% above |
| 200 week MA | $32.9 | 85% above |
AEHR has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
AEHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.00 | $2.47 | +24% |
| 2021 | $2.47 | $20.5 | +729% |
| 2022 | $20.5 | $21.0 | +2.5% |
| 2023 | $21.0 | $26.5 | +26% |
| 2024 | $26.5 | $16.5 | -38% |
| 2025 | $16.5 | $21.5 | +30% |
| 2026 YTD | $21.5 | $61.0 | +184% |
AEHR has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.